الفهرس 
Breast cancerOnly 14 pages are availabe for public view
 |  | from | 140 |  |  |
| | | from | 140 | | |
Abstract
We aimed to learn more about the potential function of the TUG-1/miR-186/SIRT3/PPAR-1/HIF-1 axis in TMX-resistant and TMX-sensitive BC patients as well as to correlate the aforementioned axis with tumor progression, various clinical manifestations, anthropometric measurements, and other metabolic biomarkers in BC. Because of this, finding a diagnostic marker and overcoming TMX resistance for improved BC therapy may be possible using this technique.
The design of the present study was divided into:
1)- This study was a prospective observational study carried out on 100 female subjects, of which 50 of them were histopathological confirmed BC patients on TMX for at least 6 months. The remaining 50 were histopathological confirmed BC patients on TMX for at least 6 months and then will be shifted to another line of treatment (either hormonal or chemotherapy) due to progression in the form of recurrence or metastasis.
2)- All subjects were informed about the tests, the protocol, the potential risks, purpose and benefits of the study and gave their informed consent. The experimental protocol was approved by the ethics committee of Faculty of Pharmacy and the Oncology Department, Faculty of medicine in ASU, and was performed in adherence to the Declaration of Helsinki Guidelines. A complete medical history, physical examination and demographic information was obtained for all participants.
3)- Yielded serum was divided into two portions. The first portion was used for extraction of TUG1 and miR-186 from plasma followed by RT-PCR, whereas the second portion was used for to assay for serum levels of SIRT3, PPAR-1 and HIF-1.
The findings of the present study were as follows:
1)- Plasma levels of TUG-1 and miR-186 were significantly elevated in TMX resistant patients when compared to TMX-sensitive patients.
2)- Serum levels of proteins SIRT3, PPAR-1 and HIF-1 were significantly deficient in TMX resistant patients compared to age-matched TMX sensitive patients.
3)- There was statistically significant association found between miR-186 and respiratory symptoms and between HIF-1 and metastases respectively in TMX resistant patients.
4)- There was no statistically significant difference found between sensitive group and resistant group regarding overall survival.
5)- Only TUG-1 and HIF-1, revealed statistically significant results in both uni-variate and multi-variate logistic regression analysis.